[
 {
  "trial": "T005",
  "source": "abstract",
  "arms": {
   "Group A (ketamine)": {
    "randomized": "35",
    "analysed": null
   },
   "Group B (propofol and fentanyl)": {
    "randomized": "35",
    "analysed": null
   }
  },
  "depression": [
   {
    "measure": "Hamilton Depression Rating (HDR) score",
    "day": -1,
    "form": "mean_sd",
    "location": "abstract (2 days before surgery)",
    "values": {
     "Group A (ketamine)": {
      "mean": "12.7",
      "sd": "5.4",
      "n": null
     },
     "Group B (propofol and fentanyl)": {
      "mean": "12.3",
      "sd": "6.0",
      "n": null
     }
    }
   },
   {
    "measure": "Hamilton Depression Rating (HDR) score",
    "day": 1,
    "form": "mean_sd",
    "location": "abstract (1 day after surgery)",
    "values": {
     "Group A (ketamine)": {
      "mean": "9.9",
      "sd": "4.1",
      "n": null
     },
     "Group B (propofol and fentanyl)": {
      "mean": "14.4",
      "sd": "3.8",
      "n": null
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. Group C (25 non-depressed patients, not randomized) left out. The abstract prints '+/-' without saying SD or SE; coded mean_sd. HDR baseline was 2 days before surgery (day -1). No n per time point; groups of 35. Pain scores at 8 and 16 h after the end of anaesthesia (A 26.6 +/- 8.7 and 24.9 +/- 8.2; B 34.3 +/- 12.0 and 31.1 +/- 8.8) fall outside the 18-30 h window and are left out. No adverse events reported."
 },
 {
  "trial": "T011",
  "source": "abstract",
  "arms": {
   "Group K": {
    "randomized": null,
    "analysed": null
   },
   "Group C": {
    "randomized": null,
    "analysed": null
   }
  },
  "depression": [],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": null,
  "note": "Abstract only. 120 patients randomized in total; the split between group K and group C is not given. PHQ-9 (1 day before surgery, POD1, POD5), VAS pain and complications are described only with P values; no numbers to extract."
 },
 {
  "trial": "T016",
  "source": "fulltext",
  "arms": {
   "Lo-K": {
    "randomized": null,
    "analysed": "226"
   },
   "Hi-K": {
    "randomized": null,
    "analysed": "223"
   },
   "Placebo (P)": {
    "randomized": null,
    "analysed": "221"
   }
  },
  "depression": [
   {
    "measure": "PHQ-8",
    "day": -1,
    "form": "count",
    "definition": "PHQ-8 ≥ 10",
    "location": "Table 3, Preoperative",
    "values": {
     "Lo-K": {
      "events": "24",
      "n": "226"
     },
     "Hi-K": {
      "events": "22",
      "n": "223"
     },
     "Placebo (P)": {
      "events": "18",
      "n": "221"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 3,
    "form": "count",
    "definition": "PHQ-8 ≥ 10",
    "location": "Table 3, POD3",
    "values": {
     "Lo-K": {
      "events": "32",
      "n": "180"
     },
     "Hi-K": {
      "events": "29",
      "n": "169"
     },
     "Placebo (P)": {
      "events": "23",
      "n": "156"
     }
    }
   },
   {
    "measure": "PHQ-8",
    "day": 30,
    "form": "count",
    "definition": "PHQ-8 ≥ 10",
    "location": "Table 3, POD30",
    "values": {
     "Lo-K": {
      "events": "9",
      "n": "130"
     },
     "Hi-K": {
      "events": "14",
      "n": "128"
     },
     "Placebo (P)": {
      "events": "24",
      "n": "137"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "NCT01690988",
   "date": null
  },
  "note": "Secondary analysis of PODCAST. Randomized numbers per arm are not in the text (Fig. 1 has no printed values); analysed = Table 1/2 sample sizes (670 analysed). Depression entries are Table 3 counts of 'symptoms suggestive of depression' (PHQ-8 of 10 or higher); POD30 is 'approximately 1 month after surgery'. Continuous PHQ-8 by arm is printed only before surgery (Table 2): Median (IQR) Placebo 2 (0–5), Lo-K 2 (0–6), Hi-K 2 (0–5); Range 0–16, 0–22, 0–14; the 'Mean (sd)' row prints 3.1 (0–5), 3.6 (0–6), 3.3 (0–5), IQR-like values in the SD place (All groups 3.3 (3.9)), so no usable SD. After surgery continuous PHQ-8 is only in Fig. 2 (no printed values) and as combined ketamine vs placebo differences: POD3 median difference 0 (95% CI –1.0 to 1.0), POD30 0 (95% CI 0.0–1.0). Missing PHQ-8: 165 at POD3, 375 at POD30. No adverse events in this report."
 },
 {
  "trial": "T024",
  "source": "fulltext",
  "arms": {
   "R (ropivacaine alone)": {
    "randomized": null,
    "analysed": "40"
   },
   "RS (ropivacaine with IV S-ketamine)": {
    "randomized": null,
    "analysed": "40"
   }
  },
  "depression": [
   {
    "measure": "EPDS at discharge",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 1, 'EPDS scores at admission' (day before surgery)",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.5",
      "sd": "2.5",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.9",
      "sd": "2.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "EPDS at discharge",
    "day": null,
    "form": "mean_sd",
    "location": "Table 4, 'EPDS scores at discharge'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "4.1",
      "sd": "3.0",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.3",
      "sd": "2.5",
      "n": "40"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4, 'Resting VAS at 24H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.4",
      "sd": "0.9",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "1.4",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4, 'Mobile VAS at 24H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "5.9",
      "sd": "1.3",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "3.8",
      "sd": "1.3",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 4, 'PCA times during 24H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "2.2",
      "sd": "2.3",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "1.7",
      "sd": "1.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4, 'Resting VAS at 48H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "1.8",
      "sd": "0.7",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "0.7",
      "sd": "0.8",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4, 'Mobile VAS at 48H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "3.4",
      "sd": "1.1",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "2.2",
      "sd": "1.1",
      "n": "40"
     }
    }
   },
   {
    "measure": "analgesic effect at 24 and 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 4, 'PCA times during 24-48H'",
    "values": {
     "R (ropivacaine alone)": {
      "mean": "0.7",
      "sd": "0.8",
      "n": "40"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "mean": "0.4",
      "sd": "0.9",
      "n": "40"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 4, Peri-operative outcomes",
    "values": {
     "R (ropivacaine alone)": {
      "nightmare": "0",
      "visual": "0",
      "dizziness": "1"
     },
     "RS (ropivacaine with IV S-ketamine)": {
      "nightmare": "25",
      "visual": "0",
      "dizziness": "21"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-01",
   "end": "2021-04"
  },
  "registration": {
   "number": "ChiCTR2000040375",
   "date": "2020-11-28"
  },
  "note": "85 women recruited and allocated; 40 per group analysed (randomized per arm not stated, Fig. 1 not printed). The design names the measure 'EPDS at discharge'; the baseline EPDS (at admission, the day before surgery) is given under the same name with day -1. The discharge day is not stated, so that entry's day is null. The design's 'analgesic effect at 24 and 48 h' is reported as three Table 4 rows (Resting VAS, Mobile VAS, PCA times), each entered under the design's name with the row named in location. Adverse events are from Table 4 'Peri-operative outcomes' (coded intraoperative): 'Dreaming' coded nightmare, 'Blurred vision' coded visual. Enrollment period is from Methods (Results don't state it); registration date printed 28/11/2020. Results text gives 'Duration of first PCA' in the reverse group order to Table 4 (not extracted)."
 },
 {
  "trial": "T026",
  "source": "fulltext",
  "arms": {
   "Group C": {
    "randomized": "30",
    "analysed": "30"
   },
   "Group K": {
    "randomized": "30",
    "analysed": "30"
   }
  },
  "depression": [
   {
    "measure": "Profile of Mood States (POMS)",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 4, 'Total depression subscale', Pre",
    "values": {
     "Group C": {
      "mean": "8.4",
      "sd": "2.8",
      "n": "30"
     },
     "Group K": {
      "mean": "8.1",
      "sd": "2.3",
      "n": "30"
     }
    }
   },
   {
    "measure": "Profile of Mood States (POMS)",
    "day": 0,
    "form": "mean_sd",
    "location": "Table 4, 'Total depression subscale', Post (2 h postoperatively)",
    "values": {
     "Group C": {
      "mean": "10.2",
      "sd": "3.4",
      "n": "30"
     },
     "Group K": {
      "mean": "5.3",
      "sd": "1.9",
      "n": "30"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 5, Diplopia, Intraoperative",
    "values": {
     "Group C": {
      "visual": "0"
     },
     "Group K": {
      "visual": "9"
     }
    }
   },
   {
    "window": "postoperative",
    "location": "Table 5, Diplopia, Postoperative",
    "values": {
     "Group C": {
      "visual": "0"
     },
     "Group K": {
      "visual": "6"
     }
    }
   },
   {
    "window": "overall",
    "location": "Table 5, Perioperative psychedelic phenomena",
    "values": {
     "Group C": {
      "hallucination": "0",
      "dissociation": "0"
     },
     "Group K": {
      "hallucination": "2",
      "dissociation": "6"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2019-07",
   "end": "2020-08"
  },
  "registration": {
   "number": "PACTR201907779292947",
   "date": "2019-07-16"
  },
  "note": "Randomized per arm taken from the tables' N = 30 (60 participated, 1:1, no losses reported; Fig. 1 not printed). Design code POMS_D, so the entries are Table 4's 'Total depression subscale' (Pre = preoperatively, day -1; Post = 2 h postoperatively, day 0). Total POMS (Table 4), not entered: Preoperative K 28.1 ± 8.0, C 27.8 ± 9.5; Postoperative K 11.9 ± 5.4, C 37.3 ± 13.0. Table 5: diplopia coded visual; 'Perioperative psychedelic phenomena' (intraoperatively and/or postoperatively) coded overall; not coded: relaxation 25 vs 0, euphoria 7 vs 0, dysphoria 1 vs 0, headache intraoperative 6 vs 0 and postoperative 7 vs 6 (K vs C). Registration date printed 16/7/2019."
 },
 {
  "trial": "T030",
  "source": "fulltext",
  "arms": {
   "Group S (esketamine)": {
    "randomized": "105",
    "analysed": "102"
   },
   "Group L (saline)": {
    "randomized": "105",
    "analysed": "100"
   }
  },
  "depression": [
   {
    "measure": "EPDS",
    "day": -1,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Pre-partum day 1",
    "values": {
     "Group S (esketamine)": {
      "events": "26",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "31",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 7,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Post-partum week 1",
    "values": {
     "Group S (esketamine)": {
      "events": "4",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "2",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 14,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Post-partum week 2",
    "values": {
     "Group S (esketamine)": {
      "events": "2",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "1",
      "n": "100"
     }
    }
   },
   {
    "measure": "EPDS",
    "day": 28,
    "form": "count",
    "definition": "EPDS ≥ 9",
    "location": "Table 2, Post-partum week 4",
    "values": {
     "Group S (esketamine)": {
      "events": "2",
      "n": "102"
     },
     "Group L (saline)": {
      "events": "1",
      "n": "100"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "intraoperative",
    "location": "Table 3, 5 min after administration",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "50",
      "hallucination": "28",
      "visual": "0"
     },
     "Group L (saline)": {
      "dizziness": "4",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "intraoperative",
    "location": "Table 3, 15 min after administration",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "66",
      "hallucination": "2",
      "visual": "2"
     },
     "Group L (saline)": {
      "dizziness": "2",
      "hallucination": "0",
      "visual": "0"
     }
    }
   },
   {
    "window": "emergence",
    "location": "Table 3, When leaving the operating room",
    "values": {
     "Group S (esketamine)": {
      "dizziness": "34",
      "hallucination": "0",
      "visual": "0"
     },
     "Group L (saline)": {
      "dizziness": "0",
      "hallucination": "0",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": null,
  "registration": {
   "number": "ChiCTR2100054332",
   "date": null
  },
  "note": "Depression entries are Table 2 counts of PPD (EPDS of nine or more, assessed by psychiatrists); 'Pre-partum day 1' is 1 day before delivery (day -1); weeks 1, 2 and 4 by telephone. Continuous EPDS is only in Fig. 3 and NRS pain only in Fig. 2 (no printed values), so no pain entries. 3 (S) and 5 (L) lost to follow-up. Adverse events (Table 3) at 5 and 15 min after esketamine (given 5 min after delivery, coded intraoperative) and 'when leaving the operating room' (spinal anaesthesia; coded emergence). visual = the Diplopia row; Blurred vision is a separate row: S 0 / 1 / 1, L 0 / 0 / 0 at 5 min / 15 min / leaving the room. Enrollment period not stated."
 },
 {
  "trial": "T059",
  "source": "fulltext",
  "arms": {
   "Treatment Arm": {
    "randomized": "30",
    "analysed": "28"
   },
   "Control Arm (saline)": {
    "randomized": "30",
    "analysed": "27"
   }
  },
  "depression": [
   {
    "measure": "Self-rating Depression Scale (SDS), at admission and discharge",
    "day": 28,
    "form": "median_iqr",
    "location": "Table 3, 'Median SDS on Day 28 (Q25, Q75)'",
    "values": {
     "Treatment Arm": {
      "median": "49.8",
      "q1": "43.1",
      "q3": "56.5",
      "n": "28"
     },
     "Control Arm (saline)": {
      "median": "53.1",
      "q1": "47.3",
      "q3": "59.0",
      "n": "27"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [],
  "blinding_check": null,
  "enrollment": {
   "start": "2020-09",
   "end": "2022-12"
  },
  "registration": {
   "number": "ChiCTR2000034069",
   "date": "2020-06-22"
  },
  "note": "60 randomized (30/30); 3 withdrew consent and 2 were excluded for continuous sedation in ICU (arms not stated); analysed 28/27 from the table headers (modified ITT). SDS at admission is not reported. 'Day 28' counts from admission (Day 0), with surgeries during the first month, so the days after the first esketamine surgery are not known; day entered as printed (28). The Table 3 'Median (Q25, Q75)' values for SDS, PCL-C and PSQI sit symmetrically around the centre (SDS 49.8 (43.1, 56.5)), which may mean another summary was mislabelled. Postoperative NPRr and NPRm are only in Fig. 2 (no printed values). Left out as not at 24/48 h (Table 2, whole postoperative period): cases with NPRr > 3, 3 (10.7 %) vs 6 (22.2 %); NPRm > 3, 9 (32.1 %) vs 17 (65.4 %); postoperative daily opioid consumption (IV morphine equivalents, mg) 26.0 (16.3, 32.5) vs 35.0 (26.4, 50.9); SAE grade 1-2 at day 28 or discharge 19 (67.9 %) vs 11 (40.7 %) (Treatment vs Control). No psychotomimetic adverse events reported."
 },
 {
  "trial": "T067",
  "source": "fulltext",
  "arms": {
   "Control group (placebo)": {
    "randomized": "45",
    "analysed": "42"
   },
   "Low esketamine group (0.2 mg/kg)": {
    "randomized": "45",
    "analysed": "42"
   },
   "High esketamine group (0.5 mg/kg)": {
    "randomized": "45",
    "analysed": "45"
   }
  },
  "depression": [
   {
    "measure": "HADS-D",
    "day": -1,
    "form": "count",
    "definition": "HADS-D ≥ 8",
    "location": "Table 3, Depression incidence, Preoperative",
    "values": {
     "Control group (placebo)": {
      "events": "15",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "20",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "16",
      "n": "45"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 1,
    "form": "count",
    "definition": "HADS-D ≥ 8",
    "location": "Table 3, Depression incidence, POD1",
    "values": {
     "Control group (placebo)": {
      "events": "12",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "5",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "1",
      "n": "45"
     }
    }
   },
   {
    "measure": "HADS-D",
    "day": 3,
    "form": "count",
    "definition": "HADS-D ≥ 8",
    "location": "Table 3, Depression incidence, POD3",
    "values": {
     "Control group (placebo)": {
      "events": "2",
      "n": "42"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "events": "0",
      "n": "42"
     },
     "High esketamine group (0.5 mg/kg)": {
      "events": "1",
      "n": "45"
     }
    }
   }
  ],
  "pain": [],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 2, 'Postoperative Agitation'",
    "values": {
     "Control group (placebo)": {
      "agitation": "3"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "agitation": "5"
     },
     "High esketamine group (0.5 mg/kg)": {
      "agitation": "2"
     }
    }
   },
   {
    "window": "overall",
    "location": "Results 3.6 Side effects (text: no participants reported)",
    "values": {
     "Control group (placebo)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "0"
     },
     "Low esketamine group (0.2 mg/kg)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "0"
     },
     "High esketamine group (0.5 mg/kg)": {
      "hallucination": "0",
      "nightmare": "0",
      "dizziness": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-06",
   "end": "2022-07"
  },
  "registration": {
   "number": "ChiCTR2100047067",
   "date": null
  },
  "note": "Depression entries are Table 3 counts with HADS-D of 8 or more; POD-1 (day before surgery) is day -1. Continuous HADS-D and the pain VAS at 2, 24, 48 and 72 h are only in Fig. 3 (no printed values), so no pain entries. Six of 135 lost (withdrawal or no follow-up): analysed 42/42/45. Postoperative agitation (Table 2) is printed as counts without percentages. Results 3.6 says no participant reported nightmares, dizziness or hallucinations; entered as 0 in every arm (window not stated, coded overall)."
 },
 {
  "trial": "T074",
  "source": "fulltext",
  "arms": {
   "Esketamine group (group E)": {
    "randomized": "50",
    "analysed": "50"
   },
   "Control group (group C)": {
    "randomized": "50",
    "analysed": "48"
   }
  },
  "depression": [
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": -1,
    "form": "count",
    "definition": "EPDS category 'Depression' (Table 4; cut-offs not stated)",
    "location": "Table 4, Preoperative depression",
    "values": {
     "Esketamine group (group E)": {
      "events": "0",
      "n": "50"
     },
     "Control group (group C)": {
      "events": "3",
      "n": "48"
     }
    }
   },
   {
    "measure": "Edinburgh Postnatal Depression Scale (EPDS)",
    "day": 2,
    "form": "count",
    "definition": "EPDS category 'Depression' (Table 4; cut-offs not stated)",
    "location": "Table 4, Postoperative depression (postoperative day 2)",
    "values": {
     "Esketamine group (group E)": {
      "events": "0",
      "n": "50"
     },
     "Control group (group C)": {
      "events": "1",
      "n": "48"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "maximum NRS pain within 24 h",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text, paragraph after Table 1",
    "values": {
     "Esketamine group (group E)": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group (group C)": {
      "median": "6",
      "q1": "5",
      "q3": "6",
      "n": null
     }
    }
   },
   {
    "measure": "NRS moving incision pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text after Fig 3, Moving incision pain 12–24 h",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "4",
      "q3": "5",
      "n": null
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "5",
      "n": null
     }
    }
   },
   {
    "measure": "NRS rest incision pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text after Fig 3, Rest incision pain 12–24 h",
    "values": {
     "Esketamine group (group E)": {
      "median": "2",
      "q1": "1",
      "q3": "2",
      "n": null
     },
     "Control group (group C)": {
      "median": "2",
      "q1": "1",
      "q3": "3",
      "n": null
     }
    }
   },
   {
    "measure": "NRS visceral pain (0-6, 6-12, 12-24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text after Fig 3, Visceral pain 12–24 h",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "2.75",
      "q3": "4.25",
      "n": null
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "5.75",
      "n": null
     }
    }
   },
   {
    "measure": "PCIA presses, rescue analgesic dose, total PCIA consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, '12–24 h postoperatively NOC of PCIA (times)'",
    "values": {
     "Esketamine group (group E)": {
      "median": "4.00",
      "q1": "2.00",
      "q3": "7.25",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "3.00",
      "q1": "2.00",
      "q3": "6.75",
      "n": "48"
     }
    }
   },
   {
    "measure": "PCIA presses, rescue analgesic dose, total PCIA consumption",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 3, '12–24 h postoperatively PCIA consumption (mL)'",
    "values": {
     "Esketamine group (group E)": {
      "median": "34.00",
      "q1": "30.00",
      "q3": "43.50",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "33.00",
      "q1": "27.00",
      "q3": "44.25",
      "n": "48"
     }
    }
   },
   {
    "measure": "pressure pain threshold and tolerance (30 min, 24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text, PPT (kgf) T2",
    "values": {
     "Esketamine group (group E)": {
      "median": "2.03",
      "q1": "1.6",
      "q3": "2.83",
      "n": null
     },
     "Control group (group C)": {
      "median": "2.15",
      "q1": "1.8",
      "q3": "2.8",
      "n": null
     }
    }
   },
   {
    "measure": "pressure pain threshold and tolerance (30 min, 24 h)",
    "day": 1,
    "form": "median_iqr",
    "location": "Results text, PTO (kgf) T2",
    "values": {
     "Esketamine group (group E)": {
      "median": "3.88",
      "q1": "2.62",
      "q3": "4.83",
      "n": null
     },
     "Control group (group C)": {
      "median": "3.85",
      "q1": "3.33",
      "q3": "4.92",
      "n": null
     }
    }
   },
   {
    "measure": "Cumulative resting pain score",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group (group E)": {
      "median": "4",
      "q1": "3",
      "q3": "5",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "5",
      "q1": "4",
      "q3": "6",
      "n": "48"
     }
    }
   },
   {
    "measure": "Cumulative moving pain score",
    "day": 1,
    "form": "median_iqr",
    "location": "Table 2",
    "values": {
     "Esketamine group (group E)": {
      "median": "11",
      "q1": "10",
      "q3": "12",
      "n": "50"
     },
     "Control group (group C)": {
      "median": "13",
      "q1": "12",
      "q3": "14.75",
      "n": "48"
     }
    }
   },
   {
    "measure": "Cumulative visceral pain score",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 2",
    "values": {
     "Esketamine group (group E)": {
      "mean": "9.14",
      "sd": "3.02",
      "n": "50"
     },
     "Control group (group C)": {
      "mean": "11.79",
      "sd": "2.47",
      "n": "48"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 5 (side effects at 24 h postoperatively)",
    "values": {
     "Esketamine group (group E)": {
      "dizziness": "4",
      "nightmare": "5",
      "visual": "1"
     },
     "Control group (group C)": {
      "dizziness": "3",
      "nightmare": "2",
      "visual": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2023-12-12",
   "end": "2025-04-18"
  },
  "registration": {
   "number": "ChiCTR2300078310",
   "date": null
  },
  "note": "Two group C dropouts (PCIA failure at 3 h, withdrawal at 8 h). Depression: Table 4 gives EPDS categories No / Mild / Depression without cut-offs; events = the 'Depression' row. Mild: preoperative E 13 (26%), C 8 (16.7%); postoperative day 2 E 2 (4%), C 7 (14.6%). No: preoperative E 37, C 37; postoperative E 48, C 40. Pain: the NRS interval entries are the 12–24 h interval, entered as day 1 (0–6 and 6–12 h left out); they and the maximum NRS within 24 h, PPT and PTO are printed in the Results text with no n. Group C visceral 12–24 h upper quartile is printed '5. 75'. The design's PCIA measure is two Table 3 rows (12–24 h presses and 12–24 h consumption; interval values, not cumulative), both under the design's name. PPT/PTO: T0/T1/T2 are not defined in the text; T2 taken as 24 h from the Methods ('30 minutes and 24 hours postoperatively') and 'preoperative and postoperative' order. Table 2 cumulative pain scores are not in the design (source names used; cumulative over the intervals to 24 h, entered as day 1). Not coded from Table 5: drowsiness 5 vs 2, nausea and vomiting 8 vs 2. Results say there was no unblinding (no guess data)."
 },
 {
  "trial": "T080",
  "source": "fulltext",
  "arms": {
   "Low-dose group (L)": {
    "randomized": "75",
    "analysed": "75"
   },
   "High-dose group (H)": {
    "randomized": "75",
    "analysed": "75"
   },
   "Control group (C)": {
    "randomized": "75",
    "analysed": "75"
   }
  },
  "depression": [
   {
    "measure": "HAMD-17",
    "day": -1,
    "form": "mean_sd",
    "location": "Table 3, Before surgery",
    "values": {
     "Low-dose group (L)": {
      "mean": "12.3",
      "sd": "6.0",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "12.6",
      "sd": "5.8",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "12.7",
      "sd": "5.4",
      "n": "75"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 3, Day 1",
    "values": {
     "Low-dose group (L)": {
      "mean": "10.3",
      "sd": "4.2",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "10.1",
      "sd": "4.1",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "14.4",
      "sd": "3.8",
      "n": "75"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 3,
    "form": "mean_sd",
    "location": "Table 3, Day 3",
    "values": {
     "Low-dose group (L)": {
      "mean": "10.5",
      "sd": "5.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "9.2",
      "sd": "3.6",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "13.5",
      "sd": "4.2",
      "n": "75"
     }
    }
   },
   {
    "measure": "HAMD-17",
    "day": 7,
    "form": "mean_sd",
    "location": "Table 3, Day 7",
    "values": {
     "Low-dose group (L)": {
      "mean": "11.9",
      "sd": "5.6",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "11.6",
      "sd": "3.9",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "12.1",
      "sd": "4.7",
      "n": "75"
     }
    }
   }
  ],
  "pain": [
   {
    "measure": "VAS (4, 8, 12, 24, 48 h)",
    "day": 1,
    "form": "mean_sd",
    "location": "Table 5, VAS T4 (24 h)",
    "values": {
     "Low-dose group (L)": {
      "mean": "2.1",
      "sd": "0.9",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "1.8",
      "sd": "1.0",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "1.7",
      "sd": "1.0",
      "n": "75"
     }
    }
   },
   {
    "measure": "VAS (4, 8, 12, 24, 48 h)",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 5, VAS T5 (48 h)",
    "values": {
     "Low-dose group (L)": {
      "mean": "1.2",
      "sd": "0.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "1.1",
      "sd": "0.9",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "0.9",
      "sd": "0.3",
      "n": "75"
     }
    }
   },
   {
    "measure": "total postoperative sufentanil consumption over 48 h",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 7, Sufentanil dosage (μg)",
    "values": {
     "Low-dose group (L)": {
      "mean": "69.2",
      "sd": "4.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "66.7",
      "sd": "5.1",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "83.0",
      "sd": "5.6",
      "n": "75"
     }
    }
   },
   {
    "measure": "PCA compressions",
    "day": 2,
    "form": "mean_sd",
    "location": "Table 7, PCA compressions",
    "values": {
     "Low-dose group (L)": {
      "mean": "5.3",
      "sd": "2.8",
      "n": "75"
     },
     "High-dose group (H)": {
      "mean": "2.1",
      "sd": "1.2",
      "n": "75"
     },
     "Control group (C)": {
      "mean": "11.5",
      "sd": "3.5",
      "n": "75"
     }
    }
   }
  ],
  "adverse_events": [
   {
    "window": "postoperative",
    "location": "Table 9 (adverse reactions after surgery)",
    "values": {
     "Low-dose group (L)": {
      "dizziness": "10",
      "nightmare": "2",
      "agitation": "0"
     },
     "High-dose group (H)": {
      "dizziness": "10",
      "nightmare": "2",
      "agitation": "0"
     },
     "Control group (C)": {
      "dizziness": "7",
      "nightmare": "0",
      "agitation": "0"
     }
    }
   }
  ],
  "blinding_check": null,
  "enrollment": {
   "start": "2021-09",
   "end": "2024-06"
  },
  "registration": null,
  "note": "ITT with last observation carried forward for HAMD; the number of dropouts is not given and every table gives N = 75 per group. Sufentanil consumption and PCA compressions (Table 7) cover the 48-h pump period (day 2); intraoperative sufentanil (design day 0) not extracted. Table 9 'Delirium' (0 in every group) coded agitation. Enrollment period from Methods; no registration number in the text. Check: the pilot values in the sample-size paragraph (day 3 control 13.5 ± 4.2, esketamine 10.5 ± 5.8) equal Table 3's day 3 values for C and L, and Table 3's baseline C 12.7 ± 5.4 and L 12.3 ± 6.0 and day 1 C 14.4 ± 3.8 equal the HDR values in this batch's T005 abstract (pmid:12088953). Table 2's header names 'L Group' twice; Table 4 prints the day 3 H vs L CI as [−2.8, 0.2] where the text has [−2.8, −0.2]."
 }
]